Allogeneic TransplantationNCT06450353
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
An observational study of Allogeneic Transplantation, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Allogeneic Transplantation
- What is being tested?
- Patient Ancestry Questionnaires
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,200 participants
- Where
- 1 siteUnited States
- Study dates
- 31 May 2024to 1 Jun 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- ≥ 18 years of age.
- Candidate for allogeneic transplantation
Who cannot join
- 1) Allogeneic stem cell transplantation not medically indicated.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Warren Fingrut, MD, 832-387-8363, wbfingrut@mdanderson.org
Warren Fingrut, MD
About this study
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).
Read the detailed description
Primary Objectives To prospectively evaluate graft options and choice of donor by patient ancestry and SES for allograft candidates at MDACC.
Secondary Objectives
- To prospectively evaluate time to transplant for allograft candidates at MDACC.
- To evaluate treatment-related mortality for allograft candidates at MDACC.
- To assess overall survival for allograft candidates at MDACC.
- To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC.
- To evaluate receipt of an optimal graft for allograft recipients at MDACC.
- Conditions
- Allogeneic Transplantation
- Being tested
- Patient Ancestry Questionnaires
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient Ancestry QuestionnairesBehavioural
Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
| Study group | Role | What they receive |
|---|---|---|
| Prospective evaluation | Participants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record. Receives: Behavioral: Patient Ancestry Questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Ancestry Questionnaire
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2024
- Study start31 May 2024
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allogeneic TransplantationStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Warren Fingrut, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06450353
- Sponsor's protocol ID
- 2024-0253
- Other IDs
- NCI-2024-04790
- Status last verified
- Jul 2026
- First submitted
- 31 May 2024
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
- ClinicalTrials.gov ID
- NCT06450353
- Acronym / sponsor ID
- 2024-0253
- Conditions
- Allogeneic Transplantation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 31 May 2024 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2029 (estimated)
- First posted
- 10 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).
Detailed description
Primary Objectives To prospectively evaluate graft options and choice of donor by patient ancestry and SES for allograft candidates at MDACC.
Secondary Objectives
- To prospectively evaluate time to transplant for allograft candidates at MDACC.
- To evaluate treatment-related mortality for allograft candidates at MDACC.
- To assess overall survival for allograft candidates at MDACC.
- To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC.
- To evaluate receipt of an optimal graft for allograft recipients at MDACC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Prospective evaluation | – | Behavioral: Patient Ancestry QuestionnairesParticipants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (2 listed)
- ≥ 18 years of age.
- Candidate for allogeneic transplantation
Key exclusion criteria (1 listed)
- 1) Allogeneic stem cell transplantation not medically indicated.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient Ancestry QuestionnairesParticipants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates. | Behavioural | Prospective evaluation |
Primary outcome
Patient Ancestry Questionnaire
Time frame: Through study completion; an average of 1 year.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Allogeneic Transplantation
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Enrolling by invitationPhase 2
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
Acute Leukemia, High Risk, Acute Leukemia Refractory
RecruitingPhase 1/2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Warren Fingrut, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Allogeneic Transplantation, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Warren Fingrut, MD ((832) 387-8363, wbfingrut@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Ancestry Questionnaire (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.